Ashish Tripathi is the founder and CEO of Tzar Labs and Director of Epigeneres Biotech, spearheading the global launch of all major breakthroughs in molecular diagnostics achieved by the company. Prior to this, Ashish was the National Head for TMTE at Edelweiss Capital and has more than 20+ years of experience in investment banking/corporate finance, M&A and corporate strategy, business services and financial planning experience across Australia, Europe, North America, Asia including the Middle East. He has worked for a variety of MNCs, including Edelweiss, Ernst & Young, Avendus, Fairfax, Mincom, NTT Communications, Deutsche Bank and Deloitte Touché Tohmatsu.
In many ways, the future of diagnostics lies in technology, machine learning, molecular biology and cutting-edge R&D. According to the Future Healthcare Journal, AI will be increasingly applied within healthcare , especially for the tasks of diagnosis and treatment recommendations, patient engagement and adherence, and administrative activities of the healthcare workforce. What does this mean for the treatment and prediction of future pandemics and for cutting edge research across medicine? Our diverse panel of experts seeks answers for you.